Safety & Antiviral Activity of Remdesivir for severe COVID-19 (Gilead 5773)

The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens with respect to the normalization of temperature and oxygen saturation through Day 14 in participants with severe coronavirus disease (COVID-19).

Imperial PI Professor Sarah Fidler
Trial Sponsor Gilead Sciences Inc.
Study type Interventional
Study status Closed to recruitment

Find out more about this study here.
ClinicalTrials.Gov record


Safety & Antiviral Activity of Remdesivir for moderate COVID-19 (Gilead 5774)

The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens compared to standard of care (SOC), with respect to the time to discharge in participants with moderate coronavirus disease (COVID-19).

Imperial PI Professor Graham Cooke
Trial Sponsor Gilead Sciences Inc.
Study type Interventional
Study status Closed to recruitment

Find out more about this study here.
ClinicalTrials.Gov record